



— 5<sup>TH</sup> ANNUAL —

# EGFR RESISTERS RESEARCH SUMMIT

An Academic Research Summit Focusing on the Advancement  
of EGFRm Treatment Paradigms through Meaningful  
Collaboration between Physician Scientist and Trainee  
Investigators and Patients





# Summit Recap



2023 EGFR-RRS Faculty & Young Investigators

The 5th annual EGFR Resisters Research Summit (EGFR-RRS) convened November 2–4, 2023, in Chicago, Illinois. The forum kicked off with an opportunity for the 15 young investigators to network with 3 patient advocates and 8 expert judge mentors during the first Small-group Table Discussions. During dinner, attendees heard from the co-founders of the EGFR Resisters, Ivy Elkins and Jill Feldman, who discussed the mission of the EGFR Resisters patient group and the critical need for research advancements in EGFRm non–small cell lung cancer (NSCLC), the history of the EGFR Resisters Research Summit, and recent breakthroughs and significant obstacles affecting the care of their fellow survivors.

Young investigators heard from Diane Legg, a patient advocate and the founder of LUNGSTRONG, to open the Summit Friday morning, prior to the research presentations. Overall, 9 trainees and 6 junior faculty presented their research within EGFR positive NSCLC—covering topics from preclinical analysis all the way to case reports—and fielded questions from an excellent panel of faculty judge mentors and patient advocates. Mentoring breakout sessions were also integrated into Friday’s session, with mentors, patients, and young investigators exploring such topics as “How to Approach a Career Track of Academic Leadership” and “Juggling Early Career and Personal Life.” The EGFR Resisters Research Summit concluded with an awards ceremony and dinner, on the heels of a collegial day and a half. The ceremony saw 5 young investigators recognized for their exemplary work—the EGFR Resisters Distinguished Young Investigator and Runner-up, as well as 3 trainees.

As part of the Annual EGFR Resisters Research Summit tradition, Jill Feldman, Ivy Elkins, and Stephen Liu participated in a recap video to provide members of the EGFR Resisters a highlight of the exciting work within EGFR-positive NSCLC. Click [here](#) to view the video.



“The EGFR Resisters Research Summit was a unique opportunity for us to meet promising young investigators and discuss the current and future state of lung cancer research. The engagement during the research presentations and in the networking opportunities throughout the day were particularly rewarding for all of the faculty. I was grateful for the chance to meet the next generation of lung cancer colleagues in a small group setting and look forward to all of the future collaborations!”

—Stephen V. Liu, MD

“I think the young investigators gain experience in presenting their work, answering questions, and also benefit greatly from connecting with the mentors and each other. As a patient advocate, I gain a lot of hope seeing this future of research!”

—Ivy Elkins



# Reflections from the EGFR Resisters Co-Founders

We are so glad that we were able to hold our 5th Annual EGFR Resisters Research Summit in November. This is always a wonderful event for us because, in addition to generating hope through meeting the young investigators who are the future of lung cancer research and learning about their work, the Summit fosters the incorporation of these investigators into the extensive and inclusive lung cancer community. The heart of the summit lies in the mentorship that blossoms between our judges and the passionate trainees and junior faculty, leading to collaboration among attendees that lasts way beyond the scope of the Summit.

We are thrilled to see so many of our alums lead ground-breaking clinical trials, present important work at oncology meetings, publish in well-recognized journals, and collaborate on projects. Over the years, a number of our alums have returned to the Summit to give special lectures and even serve as mentor judges! All of our alums recognize the importance of including the patient advocacy perspective in their work, and as patient advocates, we have developed more of an understanding and appreciation of their particular challenges as well.

Of course, the Summit is only possible with the critical assistance of Creative Educational Concepts and generous independent educational grant funding from AstraZeneca. We are so thankful for our partnerships with these organizations for our entire 5 years and look forward to many more years of continued collaboration on this important event.

Thank you on behalf of the entire EGFR Resisters Patient Community!

*—Jill & Tui*

## About the EGFR Resisters Patient Advocacy Group

Established in 2017 by 7 original members—who draw on their experience as patients, survivors, caregivers, and healthcare providers—the EGFR Resisters represent a grassroots, patient-driven community dedicated exclusively to changing EGFR-mutated lung cancer into a chronic, manageable disease. With more than 4,650 members from 99 countries across the globe, the EGFR Resisters have become a well-established and widely-known oncogene driver group that is galvanizing research efforts in meaningful and unique ways, including data gathering efforts such as Project Priority and the EGFR Resisters Research Summit, which is a Young Investigator Forum that brings together established experts with the next generation of lung cancer researchers.





## 2023 EGFR Resisters Distinguished Young Investigator Awards



2023 EGFR-RRS Young Investigator Winners

### Grand Prize | \$10,000



#### Benjamin Herzberg, MD, MSc

*Assistant Professor of Medicine*

*Columbia University Medical Center, Hebert Irving Comprehensive Cancer Center  
New York, New York*

#### [ATR Inhibitors Can Target Osimertinib Resistance in EGFR-mutated NSCLC](#)

Benjamin Herzberg, MD, MSc, is a board-certified medical oncologist specializing in the treatment of thoracic malignancies. He received his undergraduate degree from Princeton University, a medical degree from the combined Harvard Medical School and MIT Program in Health Sciences and Technology (HST), and a master of science in the history of science and medicine from Imperial College London. He completed an internship and residency training in internal medicine at Massachusetts General Hospital, where he was a Stanbury Physician-Scientist trainee, and a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, where he was Chief Fellow.

Dr. Herzberg sees patients with all types of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, mesothelioma, and thymoma. His research interests are in lung cancer and cancers with special difficulties repairing damage to their DNA. He develops clinical trials using novel agents targeting DNA repair, bringing these drugs directly to his patients in the clinic. His laboratory work aims to define new vulnerabilities in cancer cells that can be leveraged for more effective, less toxic therapy. This work has been recognized by several awards from the National Institutes of Health (NIH) and other organizations.

36

"The EGFR-RRS was hugely impactful for my professional development. Beyond the opportunity to present my work in a forum of patient advocates and world leaders in EGFR mutant lung cancer, the forum gave me the opportunity to hash out ideas with those patients and experts and my peers. I met individuals who were interested in my work, from the patients to clinical trial sponsors who can take these ideas and make them broadly impactful. It gave me a springboard from which to build ideas that hopefully will be really useful to the lung cancer and EGFR lung cancer community."



”

“This award will fund research that I presented at the conference. Specifically, I am interested in trying to defeat resistance to osimertinib before it emerges by targeting not just the “what” of resistance (what mutation is causing resistance?) but the “how” of resistance (how did this tumor develop the resistance mutation in the first place?). My hypothesis is that this process itself may be targetable, and that we can use osimertinib and other EGFR lung cancer treatments longer, and better, if we can figure out ways to get rid of resistance before it occurs. I have both laboratory models for osimertinib resistance, which we are developing and using to test this hypothesis. I will also use this award to fund work reviewing samples from our EGFR lung cancer patients to look for signatures of different resistance patterns after osimertinib treatment. I hope that, eventually, this will lead to a clinical trial testing different medicines in combination with osimertinib to see if this strategy helps patients with EGFR mutant lung cancer live longer and better.”

## Runner-up



### **Alvaro Quintanal-Villalonga, PhD**

*Assistant Attending Biologist, Lab Co-director (Assistant Professor)  
Memorial Sloan Kettering Cancer Center  
New York, New York*

### **Rb Pathway Inactivation as a Driver of Transformation from EGFR-mutant Lung Adenocarcinoma to Squamous Cell Carcinoma**

”

“The EGFR-RRS was an incredible opportunity to network with peers working in the same field and sharing the same research interests, and with reputed lung cancer researchers that provided useful scientific feedback and career advice. And remarkably, the stories that the attending patient advocates shared were extremely moving and the perfect reminder of why we do what we do, and who we do it for.”

”

“The award will be used within the project presented in the meeting, involving the Rb pathway in squamous transformation. Concretely, it will be used to help cover the cost of single-cell transcriptomic profiling of a preclinical model of adenocarcinoma-to-squamous transformation, which will allow us to study how tumor cells undergo transformation at single-cell resolution.”



# 2023 EGFR Resisters Trainee Awards

## 1<sup>ST</sup> Place



### Eric E. Gardner, PharmD, PhD

*Postdoctoral Fellow  
Weill Cornell Medicine, Meyer Cancer Center  
New York, New York*

#### On the Role of Rb1 Loss in Histological Transformation of LUAD to SCLC



"This event was an important networking opportunity during the time that I am applying for independent faculty positions—it will help me in my job search and future collaborations."



"[The grant will be used] to continue funding my lung cancer research focused on resistance to targeted therapies and tumor cell plasticity."

## 2<sup>ND</sup> Place



### Kevin Levine, MD, PhD

*Oncology Fellow  
University of Washington, Fred Hutchinson Cancer Center  
Seattle, Washington*

#### Continued EGFR Dependency in a Patient with Lung Cancer Harboring an EGFR Kinase Domain Duplication



"The EGFR-RRS was an amazing opportunity to meet other clinical fellows, post-docs, junior faculty, senior faculty, and patient advocates who all have an interest in EGFR research. Studying rare variants of EGFR is challenging from a single institution, but because of this meeting, I envision new collaborations that will allow us to better study these variants. I feel that I now have a network of colleagues from across the country that I can work with to further advance EGFR research."



"I plan to use the grant award to help cover fees for conferences related to lung cancer research. Attending these conferences will allow me to share ongoing EGFR research, as well as continue to build collaborations within the lung cancer community."



## 3<sup>RD</sup> Place



### Marie Dreyer, MD

*Fellow  
Northwestern University  
Chicago, Illinois*

#### **A Phase II Clinical Trial of Amivantamab in Patients with Metastatic NSCLC and EGFR-fusion Mutations: Future Trial**

33

"EGFR-RRS serves as an incubator for the professional development of young investigators and I am grateful for the opportunity to now be a part of this community. Meeting other trainees with similar interests from across the nation was exciting and I am thankful for the chance to grow these relationships as our careers continue. The junior faculty present at the meeting served as excellent early career role models and were quick to give advice with no subject off topic. Additionally, the ability to bring your ideas in front of senior faculty in a supportive environment is second-to-none and their wide perspective on our trial concept was invaluable. Finally, connecting with our patient advocates over the summit was a special professional moment and their stories and support make me a better oncologist."

”

"[The grant will be used for] support for clinical research coordinator efforts, statistical analysis programming, presentation materials, and travel for conference meetings/collaboration in multi-center recruitment."



# Attendees



**Mary Boulanger, MD**  
*Oncology Fellow*  
 Massachusetts General Brigham, Dana-Farber Cancer Institute  
 Boston, Massachusetts  
[@MaryBoulanger4](#)

Survivorship Care for Patients with Lung Cancer: The Association of Unmet Needs with Quality of Life and Financial Toxicity



**Allison Chang, MD, PhD**  
*Clinical Fellow in Hematology/Oncology*  
 Massachusetts General Hospital  
 Boston, Massachusetts  
[@aebchang](#)

The ASCENT Trial: Phase II Study of Induction/Consolidation Afatinib and Chemoradiation with/without Surgery for Stage III EGFR-mutant Lung Cancer



**Marie Dreyer, MD**  
*Fellow*  
 Northwestern University  
 Chicago, Illinois  
[@dreysheetmd](#)

A Phase II Clinical Trial of Amivantamab in Patients with Metastatic NSCLC and EGFR-fusion Mutations: Future Trial



**Eric E. Gardner, PharmD, PhD**  
*Postdoctoral Fellow*  
 Weill Cornell Medicine, Meyer Cancer Center  
 New York, New York

On the Role of Rb1 Loss in Histological Transformation of LUAD to SCLC



**Brinda Gupta, MD**  
*Clinical Fellow*  
 Georgetown University Hospital  
 Washington, DC

Concurrent EGFR and METex14 within a Single Tumor: A Case Report



**Amanda Herrmann, MD**  
*Hematology/Oncology Fellow*  
 University of California–San Diego  
 San Diego, California

Secondary Resistance to Osimertinib in EGFR-mutant NSCLC: A Case of an Acquired HER2 Exon 20 Insertion Demonstrating Therapeutic Response to Trastuzumab-Deruxtecan



**Benjamin Herzberg, MD**  
*Assistant Professor of Medicine*  
 Columbia University Medical Center, Hebert Irving Comprehensive Cancer Center  
 New York, New York

ATR Inhibitors Can Target Osimertinib Resistance in EGFR-mutated NSCLC



**Kevin Levine, MD, PhD**  
*Oncology Fellow*  
 University of Washington, Fred Hutchinson Cancer Center  
 Seattle, Washington  
[@Kev\\_Levine](#)

Continued EGFR Dependency in a Patient with Lung Cancer Harboring an EGFR Kinase Domain Duplication



**Shipra Maheshwari, MD**  
*Hematology/Oncology Second Year Fellow*  
 University of Virginia  
 Charlottesville, Virginia

Impact of Reflexive Inhouse Next-generation Sequencing on Timing of Treatment and/or Surgery as Well as Overall Survival in Patients with Non-squamous Non-small Cell Lung Cancer with EGFR and Other Actionable Driver Mutations



**Regan Memmott, MD, PhD**  
*Assistant Professor*  
 The Ohio State University Comprehensive Cancer Center  
 Columbus, Ohio

A Phase Ib Study of Osimertinib and Tegavivint as First-line Therapy in Patients with Metastatic EGFR-mutant Non-small Cell Lung Cancer (NSCLC)



## Attendees



**Koosha Paydary, MD, MPH, MSc**

*Assistant Professor of Medicine  
Rush University Medical Center  
Chicago, Illinois*

Concomitant Use of CYP3A4 Inhibitors/  
Inducers and Reported Outcomes  
Associated with the Use of Osimertinib  
among Patients with EGFR-mutated  
Non-small Cell Lung Cancer: A Correlative  
Analysis Using Real-world Data



**Alvaro Quintanal-Villalonga, PhD**

*Assistant Attending Biologist, Lab  
co-director (Assistant Professor)  
Memorial Sloan Kettering Cancer Center  
New York, New York*

@AlvaroQuintanal

Rb Pathway Inactivation as a Driver of  
Transformation from EGFR-mutant Lung  
Adenocarcinoma to Squamous Cell Carcinoma



**Susan Scott, MD**

*Assistant Professor  
Johns Hopkins University School of  
Medicine  
Baltimore, Maryland*

@susanscottmd

First-line Osimertinib in NSCLC Harboring  
Uncommon EGFR Mutations Including  
Atypical Exon 19 Mutations and Compound  
Mutations



**Muhammad Shahid, DO**

*Fellow  
Henry Ford Cancer Institute  
Detroit, Michigan*

Compound EGFR L833V/H835L Mutation in a  
Patient with Metastatic Non-small Cell Lung  
Cancer



**Lova Sun, MD**

*Assistant Professor  
Perelman School of Medicine,  
University of Pennsylvania  
Philadelphia, Pennsylvania*

@LovaSunMD

Characteristics of Long-term Survivors with  
EGFR Mutant (EGFRm) Metastatic Non-  
small Cell Lung Cancer (mNSCLC) Treated  
in the Pre-osimertinib Era



# At-a-Glance

Massachusetts General Hospital  
*Boston, Massachusetts*

Georgetown University Hospital  
*Washington, DC*

University of California—San Diego  
*San Diego, California*

Weill Cornell Medicine,  
Meyer Cancer Center  
*New York, New York*

University of Washington,  
Fred Hutchinson Cancer Center  
*Seattle, Washington*

Northwestern University  
*Chicago, Illinois*

Massachusetts General,  
Dana-Farber Cancer Institute  
*Boston, Massachusetts*

Henry Ford Cancer Institute  
*Detroit, Michigan*

University of Virginia  
*Charlottesville, Virginia*

Memorial Sloan Kettering Cancer Center  
*New York, New York*


Perelman School of Medicine,  
University of Pennsylvania  
*Philadelphia, Pennsylvania*

Columbia University Medical Center,  
Hebert Irving Comprehensive Cancer Center  
*New York, New York*

Rush University Medical Center  
*Chicago, Illinois*

The Ohio State University  
Comprehensive Cancer Center  
*Columbus, Ohio*

Johns Hopkins University School of Medicine  
*Baltimore, Maryland*





# Faculty



2023 EGFR-RRS Faculty



**Zofia Piotrowska, MD, MHS (chair)**  
*Assistant Professor, Medicine, Harvard Medical School  
 Assistant in Medicine, Medicine, Massachusetts General Hospital  
 Boston, Massachusetts*




**Jessica Donington, MD, MSCR**  
*Professor of Surgery  
 Chief Section Thoracic Surgery  
 University of Chicago  
 Chicago, Illinois*



**Mary Jo Fidler, MD**  
*Professor of Medicine  
 Rush Medical College  
 Section Chief of Medical Oncology  
 Rush University Medical Center  
 Division of Hematology, Oncology, and Cell Therapy  
 Chicago, Illinois*



**John V. Heymach, MD, PhD**  
*Chair and Professor, Department of Thoracic/Head and Neck Medical Oncology  
 MD Anderson Cancer Center  
 Houston, Texas*



**Stephen V. Liu, MD**  
*Associate Professor of Medicine, Georgetown University  
 Director, Thoracic Oncology and Head of Developmental Therapeutics  
 Lombardi Comprehensive Cancer Center  
 Georgetown University  
 Washington, DC*



**Christine M. Lovly, MD, PhD**  
*Associate Professor of Medicine, Division of Hematology-Oncology  
 Ingram Associate Professor of Cancer Research  
 Vanderbilt University Medical Center and  
 Vanderbilt Ingram Cancer Center  
 Nashville, Tennessee*



**Joshua Sabari, MD**  
*Assistant Professor of Medicine  
 New York University School of Medicine, NYU Langone Health  
 Perlmutter Cancer Center  
 New York, New York*



**Helena Yu, MD**  
*Associate Attending  
 Research Director, Thoracic Oncology Service  
 Memorial Sloan Kettering Cancer Center  
 New York, New York*



## Patient Advocates



**Diane Legg**  
*Founder, LUNGSTRONG  
Boston, Massachusetts*



**Ivy Elkins, MBA**  
*Co-Founder, EGFR Resisters  
EGFR+ NSCLC Patient  
Evanston, Illinois*



**Jill Feldman, MA**  
*Co-Founder, EGFR Resisters  
EGFR+ NSCLC Patient  
Deerfield, Illinois*



2023 EGFR-RRS Patient Advocates

## Professional Presentation Coaches



**Stephanie Roberson Barnard**  
*Listen Write Present, LLC  
Greensboro, North Carolina*




**Paul Casella**  
*Health Care communications Group  
University of Iowa Carver College of Medicine  
Iowa City, Iowa*



# Educational Highlights

## Presentation Skills Enhancement Workshop

To augment the professional development aspects of the EGFR-RRS, 2023 participants had the opportunity to receive individual coaching sessions by a team of experts from Listen Write Present. Young investigators who participated in the one-on-one pre-program coaching sessions received expert advice and critique of their presentation and public speaking skills, and were given a copy of the book *Listen. Write. Present.*, which was written by the Listen Write Present team. In addition, the expert coaches provided participants with tips for effective navigation of expert Q&A and research defense.



PRE-EVENT

POST-EVENT

Following coaching and abstract presentations, average participant confidence in their ability to present scientific information to peers increased from

**2.44 to 3.0\***

*\* on a 4 point scale*

PRE-EVENT

POST-EVENT

Similarly, average participant confidence in ability to defend their research following the event increased from

**2.44 to 3.0\***

*\* on a 4 point scale*



# Educational Highlights

## What Participants Value Most



"I appreciated the opportunity to hear from patients directly and learn from their experiences."



"The chance to interact with world-leading faculty in an intimate, low-pressure setting; and the ability to present work and solicit real feedback."



**Alvaro Quintanal-Villalonga**  
@AlvaroQuintanal

@EGFRSummit - what an amazing and inspiring meeting. Thankful to @EGFRResisters, @CE\_Concepts, faculty, and particularly to patient advocates who, with their generosity at sharing their stories, keep us researchers on track and remind us why we do what we do. Thank you. #LCAM23

**CE Concepts** @CE\_Concepts · Nov 3  
Program chair @ZPiotrowskaMD presents introductory remarks, kicking off #EGFRSummit!  
#MedTwitter #MedX #MedEd #EGFR @EGFRResisters



12:01 PM · Nov 5, 2023 · 566 Views



"The EGFR Resisters Research Summit was an incredible opportunity to learn about ongoing research for EGFR lung cancer, practice presenting research, learn from patient advocates, and network with fellows and attendings, which could lead to future collaborations."



## Educational Highlights

### Mentoring Moments and Small-group Networking Sessions

For this year's EGFR-RRS, small groups of participants, along with faculty mentors, had the opportunity to introduce themselves in a small group setting during the Mentoring Moment Small-group Discussions.



"There was great work being done by the trainees and young investigators focused on overcoming, and even preventing, resistance. It was a very rewarding experience—with dynamic, engaging discussions, thought provoking conversations, and a chance to connect with these rising stars."

—Stephen V. Liu, MD

### GROUP TABLE TOPICS

- How to Approach a Career Track of Academic Leadership
- When to Say Yes? How to Say No? Seeking Mentorship
- Cooperative Groups Demystified
- Interacting with Pharma
- Social Media
- Juggling Early Career and Personal Life
- Clinical Trial Design
- Working with Patient Advocates



"The intimate nature of the conference allowed for networking in both formal and informal settings."



## HOW ATTENDING THE SUMMIT WILL Impact Young Investigators' Careers



"I've made new connections professionally and I plan on staying in contact with LCRF, IASLC and the EGFR Resister community as I transition to an independent position."



"Overall, an outstanding experience. An incredible opportunity to learn from current and future leaders in the field and expand my personal and professional network."

## BEYOND THE SUMMIT Making a Difference

Following this year's 5th Annual EGFR Resisters Research Summit, our team of advocates, mentor judges, and young investigators had the chance to participate in LUNgevity's Breathe Deep TOGETHER 5K in Chicago. Our team, led by Jill Feldman, raised \$2,320 to support lung cancer research, far surpassing the goal of \$750!





# Professional Updates from the 2022 Cohort of EGFR-RRS Young Investigators

## Publications

- Abu Rous F**, Li P, Carskadon S, et al. Brief report: prognostic relevance of 3q amplification in squamous cell carcinoma of the lung. *JTO Clin Res Rep*. 2023;4(4):100486.
- Abu Rous F**, Riano I. Challenges faced by J-1 international medical graduates (IMGs) during COVID-19 pandemic. *Cancer Invest*. 2023;1–4.
- Lee M, **Abu Rous F**, Borczuk A, et al. *Targeting Oncogenic Driver Mutations in Lung Cancer*. Cambridge, England: Cambridge University Press; 2023.
- Safa H, **Abu Rous F**, Belani N, et al. Emerging biomarkers in immune oncology to guide lung cancer management. *Target Oncol*. 2023;18(1):25–49.
- Bestvina CM**, Garassino MC, Neal JW, et al. Early-stage lung cancer: using circulating tumor DNA to get personal. *J Clin Oncol*. 2023;41(25):4093–4096.
- Burns L, Hsu CY, Whisenant JG, [...] **Bestvina CM**, et al. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT). *Lung Cancer*. 2023;186:107423.
- Cameron RB, Hines JB, Torri V, [...] **Bestvina CM**, et al. What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? *Ther Adv Med Oncol*. 2023;15:17588359231198446.
- Feldt SL, **Bestvina CM**. The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications. *Cancers (Basel)*. 2023;15(11):2998.
- Hines JB, Bowar B, Levine E, [...] **Bestvina CM**. Targeted toxicities: protocols for monitoring the adverse events of targeted therapies used in the treatment of non-small cell lung cancer. *Int J Mol Sci*. 2023;24(11):9429.
- Kalchiem-Dekel O, **Bestvina CM**, Gainor JF, et al. Response to Provenzano et al. and De Carlo et al. *J Thorac Oncol*. 2023;18(2):e13–e14.
- Katipally RR, Spurr LF, Gutiontov SI, [...] **Bestvina CM**, et al. *STK11* inactivation predicts rapid recurrence in inoperable early-stage non-small-cell lung cancer. *JCO Precis Oncol*. 2023;7:e2200273.
- Negrao MV, Araujo HA, Lamberti G, [...] **Bestvina CM**, et al. Comutations and KRASG12C inhibitor efficacy in advanced NSCLC. *Cancer Discov*. 2023;13(7):1556–1571.
- Rouhani SJ, **Bestvina CM**. Immunotherapy partners after progression: right place, right time? *Cancer*. 2023;129(2):181–183.
- Stahlbaum D, Jablonski R, Streck ME, **Bestvina CM**, et al. Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis. *Respir Med*. 2023;217:107330.
- Tran MC, Strohbehm GW, Karrison TG, [...] **Bestvina CM**. Brief report: discordance between liquid and tissue biopsy-based next-generation sequencing in lung adenocarcinoma at disease progression. *Clin Lung Cancer*. 2023;24(3):e117–e121.
- Carneiro BA, Papadopoulos KP, Strickler JH, [...] **Bestvina CM**, et al. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serlutamab talirine: safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. *Neurooncol Adv*. 2022;5(1):vdac183.
- Korpics MC, Katipally RR, Partouche J, [...] **Bestvina CM**, et al. Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and immunotherapy. *Int J Radiat Oncol Biol Phys*. 2022;114(4):645–654.
- Spurr LF, Martinez CA, Kang W, [...] **Bestvina CM**, et al. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. *Nat Cancer*. 2022;3(12):1498–1512.



- Chow A, Uddin FZ, Liu M, [...] **Chan JM**, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. *Immunity*. 2023;56(1):93–106.e6.
- Pai JA, Hellmann MD, Sauter JL, [...] **Chan JM**, et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. *Cancer Cell*. 2023;41(4):776–790.e7.
- Chen MF**, Chaft JE. Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review. *Transl Lung Cancer Res*. 2023;12(2):337–345.
- Chen MF**, Harada G, Liu D, et al. Brief report: tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to “false” decreases in renal function. *J Thorac Oncol*. 2023:S1556-0864(23)02247-5.
- Chen MF**, Piotrowska Z, Yu HA. POSing the question: MARIPOSA-2, do the ends justify the means? *Ann Oncol*. 2023:S0923-7534(23)05065-2.
- Chen MF**, Yang SR, Shia J, et al. Response to repotrectinib after development of *NTRK* resistance mutations on first- and second-generation TRK inhibitors. *JCO Precis Oncol*. 2023;7:e2200697.
- McLaughlin K, Tan KS, Dycoco J, **Chen MF**, et al. Superior sulcus non-small cell lung cancers (Pancoast tumors): current outcomes after multidisciplinary management. *J Thorac Cardiovasc Surg*. 2023;166(6):1477–1487.e8.
- Thummalapalli R, Choudhury T, Ehrich F, [...] **Chen MF**, et al. Lorlatinib tolerability and association with clinical outcomes in patients with advanced ALK- or ROS1-rearranged NSCLC: a brief report. *JTO Clin Res Rep*. 2023;4(8):100546.
- Roy S, Sun Y, Morgan SC, [...] **Cueto-Márquez AE**, et al. Effect of prior local therapy on response to first-line androgen receptor axis targeted therapy in metastatic castrate-resistant prostate cancer: a secondary analysis of the COU-AA-302 trial. *Eur Urol*. 2023;83(6):571–579.
- de Miguel FJ**, Gentile C, Feng WW, et al. Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. *Cancer Cell*. 2023;41(8):1516–1534.e9.
- Elbahrawy MM**, Kamel MK, Rodriguez-Quintero JH, et al. Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non-small cell lung cancer. *J Thorac Cardiovasc Surg*. 2023:S0022-5223(23)00857-7.
- Rodriguez-Quintero JH, Kamel MK, Dawodu G, **Elbahrawy M**, et al. Underutilization of systemic therapy in patients with NSCLC undergoing pneumonectomy: a missed opportunity for survival. *JTO Clin Res Rep*. 2023;4(8):100547.
- Rodriguez-Quintero JH, Kamel MK, Jindani R, **Elbahrawy M**, et al. The effect of neoadjuvant therapy on esophagectomy for cT2N0M0 esophageal adenocarcinoma. *Ann Surg Oncol*. 2023.
- El Zarif T, Nassar AH, Adib E, (**Gleason**) **Fitzgerald B**, et al. Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-international (CATCH-IT) consortium. *J Clin Oncol*. 2023;41(21):3712–3723.



“I have met many close friends and colleagues through the EGFR Resisters. They have helped me find a strong research community as well as support throughout many struggles of being a junior faculty member. I have also been fortunate enough to find several strong research advocates willing to work with me on meaningful collaborations! I am very thankful for this group!”

—Christine Bestvina, MD



- Marks JA**, Liu SV. NSCLC with synchronous EGFR mutations in Li Fraumeni syndrome: a case report. *JTO Clin Res Rep*. 2023;4(6):100521.
- Marks JA**, Wang X, Fenu EM, et al. TP53 in AML and MDS: the new (old) kid on the block. *Blood Rev*. 2023;60:101055.
- Tiu A, **Marks J**, Aljuaid R, et al. Multiple myeloma with central nervous system relapse presenting as right pupil-sparing complete third nerve palsy. *Am J Hematol*. 2022;97(12):1666–1668.
- Baca SC, Seo JH, Davidsohn MP, [...] **Meador C**, et al. Liquid biopsy epigenomic profiling for cancer subtyping. *Nat Med*. 2023;29(11):2737–2741.
- Dagogo-Jack I, Kiedrowski LA, Heist RS, Lin JJ, **Meador CB**, et al. Efficacy and tolerability of *ALK/MET* combinations in patients with *ALK*-rearranged lung cancer with acquired *MET* amplification: a retrospective analysis. *JTO Clin Res Rep*. 2023;4(8):100534.
- Denize T, **Meador CB**, Rider AB, et al. Concordance of *ASCL1*, *NEUROD1* and *POU2F3* transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma. *Histopathology*. 2023;83(6):912–924.
- Mansur A, Potter AL, Nees AT, Sands JM, **Meador CB**, et al. Role of adjuvant chemotherapy in early-stage combined small cell lung cancer. *Ann Thorac Surg*. 2023;116(6):1142–1148.
- Meador CB**, Gainor JF. Letter to the editor reply: Kleebayoon et al. *Clin Lung Cancer*. 2023;24(5):e162-e163.
- Meador CB**, Naranbhai V, Hambelton G, et al. Brief report: declining rates of SARS-CoV-2 vaccine uptake among patients with thoracic malignancies. *Clin Lung Cancer*. 2023;24(4):353–359.
- Meador CB**, Piotrowska Z. Biology and impact of lineage plasticity in *ALK*-positive NSCLC: a narrative review. *Transl Lung Cancer Res*. 2023;12(4):837–856.
- Qian Y, Galan-Cobo A, Guijarro I, [...] **Meador CB**, et al. MCT4-dependent lactate secretion suppresses antitumor immunity in *LKB1*-deficient lung adenocarcinoma. *Cancer Cell*. 2023;41(7):1363–1380.e7.
- Desai AP, Adashek JJ, **Reuss JE**, et al. Perioperative immune checkpoint inhibition in early-stage non-small cell lung cancer: a review. *JAMA Oncol*. 2023;9(1):135–142.
- Guo MZ, Balaji A, Murray JC, **Reuss JE**, et al. Infectious complications in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. *Clin Lung Cancer*. 2023;24(7):613–620.
- Parekh J, Parikh K, **Reuss JE**, et al. Current approaches to neoadjuvant immunotherapy in resectable non-small cell lung cancer. *Curr Oncol Rep*. 2023;25(8):913–922.
- Schubert L, Elliott A, Le AT, [...] **Reuss JE**, et al. *ERBB* family fusions are recurrent and actionable oncogenic targets across cancer types. *Front Oncol*. 2023;13:1115405.
- Rosner S, **Reuss JE**, Zahurak M, et al. Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer. *Clin Cancer Res*. 2023;29(4):705–710.
- Yeung V, Zaemes J, Yeh J, [...] **Reuss JE**, et al. High levels of expression of trop-2 in thymic epithelial tumors. *Lung Cancer*. 2023;184:107324.
- Yeung V, Sackstein P, Grant NN, [...] **Reuss JE**, et al. Use of erdafitinib in *FGFR3*-mutated recurrent respiratory papillomatosis. *JCO Precis Oncol*. 2022;6:e2200435.
- Banla LI, Tzeng A, Baillieux JP, [...] **Rotow JK**, et al. Pneumonitis in patients receiving thoracic radiotherapy and osimertinib: a multi-institutional study. *JTO Clin Res Rep*. 2023;4(10):100559.
- Brea E, **Rotow J**. Targeted therapy for non-small cell lung cancer: first line and beyond. *Hematol Oncol Clin North Am*. 2023;37(3):575–594.
- Gandhi MM, Ricciuti B, Harada G, [...] **Rotow J**. Amplification of wild-type *RET* represents a novel molecular subtype of several cancer types with clinical response to selpercatinib. *JCO Precis Oncol*. 2023;7:e2300295.



Hernandez CL, Lynch DM, Golash AJ, [...] **Rotow J**, et al. Anaphylaxis and systemic mastocytosis controlled with KIT inhibitors in a patient with metastatic lung adenocarcinoma. *Ann Allergy Asthma Immunol.* 2023;131(5):668–670.

Ji J, Aredo JV, Piper-Vallillo A, Huppert L, **Rotow JK**, et al. Osimertinib in NSCLC with atypical *EGFR*-activating mutations: a retrospective multicenter study. *JTO Clin Res Rep.* 2023;4(3):100459.

Makarem M, **Rotow JK**. Genotype versus phenotype: defining predictive biomarkers of immunotherapy response. *J Thorac Oncol.* 2023;18(12):1615–1617.

**Rotow JK**, Lee JK, Madison RW, et al. Real-world genomic profile of *EGFR* second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib. *J Thorac Oncol.* 2023:S1556-0864(23)02263-3.

**Rotow J**, Patel JD, Hanley MP, et al. Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of *EGFR*-mutant and *RET* fusion-positive lung cancers. *Clin Cancer Res.* 2023;29(16):2979–2987.

Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, **Sabari JK**, et al. Adagrasib in advanced solid tumors harboring a *KRASG12C* mutation. *J Clin Oncol.* 2023;41(25):4097–4106.

Cho BC, Kim DW, Spira AI, [...] **Sabari JK**, et al. Amivantamab plus lazertinib in osimertinib-relapsed *EGFR*-mutant advanced non-small cell lung cancer: a phase 1 trial. *Nat Med.* 2023;29(10):2577–2585.

Cho BC, Simi A, **Sabari J**, et al. Amivantamab, an epidermal growth factor receptor (*EGFR*) and mesenchymal-epithelial transition factor (*MET*) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. *Clin Lung Cancer.* 2023;24(2):89–97.

Kim TM, Girard N, Leighl NB, **Sabari J**, et al. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated *EGFR* Exon 20 insertion-mutated non-small-cell lung cancer. *Future Oncol.* 2023.

Moreira AL, **Sabari JK**. Seeing beyond the smoke: reclassifying lung cancer by smoking-related mutational signatures. *J Thorac Oncol.* 2023;18(4):396–398.

Negrao MV, Spira AI, Heist RS, [...] **Sabari JK**. Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with *KRASG12C*-mutated non-small-cell lung cancer who have untreated CNS metastases. *J Clin Oncol.* 2023;41(28):4472–4477.

Park K, **Sabari JK**, Haura EB, et al. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. *Lung Cancer.* 2023;178:166-171.

Thummalapalli R, Bernstein E, Herzberg B, [...] **Sabari JK**, Arbour KC. Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced *KRAS G12C*-mutant non-small cell lung cancer. *JCO Precis Oncol.* 2023;7:e2300030.

Zhou C, Tang KJ, Cho BC, [...] **Sabari JK**, et al. Amivantamab plus chemotherapy in NSCLC with *EGFR* exon 20 insertions. *N Engl J Med.* 2023.



“I can't stress enough how impactful and relevant attending the *EGFR* Resisters Research Summit was for me. I first attended online in 2020 to present my research and again in 2022 as an alumnus to talk about collaborating and networking in Science. As a cancer biologist working fully in the lab, I often need to be reminded of what our final goal is, which is helping and improving the lives of cancer patients. Being in the same room with top mentors, experts in the field, young physicians, and the amazing *EGFR* Resisters is a must-have experience that anyone working on *EGFR* lung cancer should have at least once. I have nothing but admiration for the work that Jill, Ivy, and the rest of the Resisters do. Wherever I go, I proudly advocate for them, and share that I got to know them and the *EGFR* Resisters during my career working in lung cancer.”

—Fernando de Miguel, PhD



- Jusue-Torres I, Tiv R, Ricarte-Filho JC, [...] **Shimamura T**, et al. Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality. *Sci Rep*. 2023;13(1):4107.
- Lee JM, McNamee CJ, Toloza E, [...] **Shum E**, et al. Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives. *J Thorac Oncol*. 2023;18(11):1458–1477.
- Takahashi N, Hao Z, Villaruz LC, [...] **Shum E**, et al. Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial. *JAMA Oncol*. 2023:e234025.
- Triphuridet N, Zhang SS, Nagasaka M, [...] **Shum E**. Low-dose computed tomography (LDCT) lung cancer screening in Asian female never-smokers is as efficacious in detecting lung cancer as in Asian male ever-smokers: a systematic review and meta-analysis. *J Thorac Oncol*. 2023;18(6):698–717.
- Kareff SA, Sridhar A, Dhawan N, Anampa-Guzman A, **Singhi EK**, Velazquez AI. The democratization of hematology-oncology medical education during the COVID-19 pandemic. *Cancer Invest*. 2023;41(6):548–558.
- Singhi EK**, Feldman J, West HJ. The Multidisciplinary Cancer Conference. *JAMA Oncol*. 2023;9(2):288.
- Singhi EK**, Mott F, Worse M, et al. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non-small cell lung cancer. *Oncol Lett*. 2023; 25(6):262.
- Singhi EK**, West HJ. Rethinking the treatment approach to resectable non-small cell lung cancer: do new approvals always translate to clinical value? American Society of Clinical Oncology (ASCO) Daily News website. <https://dailynews.ascopubs.org/do/rethinking-treatment-approach-resectable-non-small-cell-lung-cancer-do-new-approvals>. Published May 17, 2023.
- Grant M, Aredo J, Starrett J, **Stockhammer P**, et al. Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. *Clin Cancer Res*. 2023;29(11):2123–2130.
- Stockhammer P**, Baumeister H, Ploenes T, et al. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. *Lung Cancer*. 2023;185:107360.
- Stockhammer P**, Grant M, Wurtz A, et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. *J Thoracic Oncol*. 2023;S1556-0864(23)02264-5.
- Vakkalagadda CV**, Patel JD. Addition of trastuzumab deruxtecan to selpercatinib in a patient with RET fusion driven NSCLC and an acquired HER2 amplification: case report. *JTO Clin Res Rep*. 2023:100603.
- Melody M, St. Pierre F, Helenowski I, Pearse WB, **Vakkalagadda CV**, et al. Impact of extranodal disease involvement on outcomes in post-transplant lymphoproliferative disorder. *Blood*. 2022;140(Suppl 1):6674–6675.
- Melody M, St. Pierre F, Helenowski I, Pearse WB, **Vakkalagadda CV**, et al. Posttransplant lymphoproliferative disorder (PTLD) following transplantation at Northwestern University: choice of immunosuppressive agents does not impact outcomes in PTLD. *Blood*. 2022;140(Suppl 1):3833–3834.

## Collaborative Publications among EGFR-RRS 2022 Young Investigators

- Abu Rous F**, **Singhi EK**, Sridhar A, et al. Lung cancer treatment advances in 2022. *Cancer Invest*. 2023;41(1):12–24.
- Berger A, Mullen R, Bernstein K, [...] **Shum E**, [...] **Sabari J**, et al. Extended survival in patients with non-small-cell lung cancer-associated brain metastases in the modern era. *Neurosurgery*. 2023;93(1):50–59.
- Ohri N, Jolly S, Cooper BT, [...] **Shum E**, **Sabari JK**, et al. Selective personalized radioimmunotherapy for locally advanced non-small-cell lung cancer trial. *J Clin Oncol*. 2023;JCO2300627.
- Marks JA**, Wilgucki M, Liu SV, **Reuss JE**. Antibody-drug conjugates in non-small cell lung cancer: emergence of a novel therapeutic class. *Curr Oncol Rep*. 2022;24(12):1829–1841.
- Yeh J, **Marks JA**, Alzeer AH, [...] **Reuss JE**, et al. Remarkable intracranial response to sotorasib in a patient with KRASG12C-mutated lung adenocarcinoma and untreated brain metastases: a case report. *JTO Clin Res Rep*. 2022;3(12):100428.



## Presentations

### 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

June 2–6, 2023; Chicago, Illinois

**Abu Rous F**, Li P, Carskadon S, et al. Prognostic relevance of 3q amplification (AMP) in a racially diverse patient population with advanced squamous cell carcinoma of the lung. Abstract e15142.

**Bestvina CM**, Waters D, Morrison L, et al. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC). Abstract 6638.

**Chen MF**, Ma J, Kris MG, et al. Predictors of benefit to radiation for oligoprogressive disease in *EGFR*-mutant metastatic non-small cell lung cancer patients treated with osimertinib. Abstract e21127.

**Chen MF**, Yang SR, Tao J, et al. Tumor-agnostic genomic and clinical analysis of solid tumors with *BRAF* fusions. Abstract 3146.

**Marks JA**, Gandhi N, Halmos B, et al. Updated molecular analysis of *MET* exon 14 skipping mutations (*MET*ex14) in non-small cell lung cancer (NSCLC). Abstract 9095.

**Reuss JE**, Gandhi N, Walker P, et al. Spectrum of acquired *KRAS* mutations in driver mutation-positive non-small cell lung cancer. Abstract 9069.

**Reuss JE**, Gandhi SG, Spigel DR, et al. RAMP 202: a phase 2 study of avutemetinib (VS-6766) ± defactinib, in patients with advanced *KRAS* G12V mutant non-small cell lung cancer (NSCLC). Abstract 9100.

**Reuss JE**, Wonser D, Smith KN, et al. A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non-small-cell lung cancer. Abstract TPS9152.

**Shum E**, Li W, Sequist LV, et al. Preliminary results from the female Asian nonsmoker screening study (FANSS). Abstract 8510.

**Stockhammer P**, Grant MJ, Wurtz A, et al. Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with *EGFR*-mutant lung cancer. Abstract 9104.

### 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

January 19–21, 2023; San Francisco, California

**Vakkalagadda C**, Mukit S, Kocherginsky M, et al. A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic *BRAF*-mutated colorectal cancer refractory to standard therapy. Abstract TPS262.



“It is hard to put into words the impact that this conference has had on me both personally and professionally. Between the meaningful, hands-on mentorship provided by leaders in the field, the ability to network with colleagues ‘rising through the ranks’ such as yourself, and make new lifetime friends, this is not a conference that you want to miss!”

—Joshua Reuss, MD



**2023 International Association for the Study of Lung Cancer (IASLC) Targeted Therapy in Lung Cancer Meeting**  
February 22–25, 2023; Santa Monica, California

**Abu Rous F**, Li P, Abushukair H, et al. Prognostic and predictive relevance of 3q amplification in squamous cell carcinoma of the lung. Poster P20.

**Chen MF**, Liu D, DeMatteo R, et al. Lung cancer approved tyrosine kinase inhibitors that inhibit MATE-1 can lead to “false” decreases in renal function. Poster P03.

**Marks JA**, Yin J, Halmos B, et al. MET exon 14 skipping mutation in non-small cell lung cancer (NSCLC): an analysis by specific mutation, histology, and smoking status. Poster P02.

**Reuss J**. Checkpoint inhibition for driver mutations – is there a way forward? Presentation S1.07.

**Rotow J**. EGFR acquired resistance: C797 and bypass pathways. Presentation S1.03.

**Sabari J**. MET Exon 14. Presentation S1.06.

**Stockhammer P**, Grant M, Wurtz A, et al. Co-occurring alterations in multiple tumor suppressor genes are associated with worse outcomes in patients with EGFR-mutant lung cancer. PosterP07.

**2023 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer**  
September 9–12, 2023; Singapore

**Bestvina CM**. Assessment for systemic therapy in local-regional NSCLC. Educational Session ES14.06.

**Chen M**, Harada G, Liu D, et al. Beware: tyrosine kinase inhibitors for lung cancer that inhibit MATE-1 can lead to “false” decreases in renal function. Poster P2.12-02.

**Meador C**, Denize T, Rider AB, et al. Spatiotemporal heterogeneity of transcription factor-based subtype assignment in small cell lung carcinoma. Poster P2.13-05.

**Rotow J**. Post-progression treatment options in patients with metastatic NSCLC. Oral Presentation IS18.05.

**Shum E**, Li W, Bell J, et al. Preliminary results from the female Asian nonsmoker screening study (FANSS). Oral Presentation OA16.04.

**Singhi EK**, Desai A, **Abu Rous F**, et al. Assessing availability and demand for patient-friendly resources in lung cancer care: the patient perspective. Oral Presentation OA10.03.

**Vakkalagadda C**, Dressler D, Fuchs J, et al. Early-stage EGFR mutated NSCLC: outcomes after surgical resection at a large academic medical center. Poster EP07.04-10.

**European Society for Medical Oncology (ESMO) Congress 2023**  
October 20–24, 2023; Madrid, Spain

**Chen MF**, Rosen E, Falcon C, et al. Genomics of early progression on seliperatinib in patients with RET fusion-positive lung cancers. Abstract 1385P.

**Reuss J**, Gandhi N, Walker P, et al. Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer. Abstract 1399P.

**Reuss J**, Marrone M, Crawford A, et al. Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: a SEER Medicare database analysis. Abstract 1470P.

**Rotow JK**, Waqar SN, Papadopoulos KP, et al. First-in-human study of ABBV-637, an EGFR-targeting BCL-XL-inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC). Abstract 1318MO.

**Sabari J**. Current and future directions for EGFR exon 20 insertion mutations in NSCLC.



**2023 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress**

March 6–8, 2023; Paris, France

**Chen MF**, Yang SR, Chang J, et al. Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy. Abstract 74P.

**American Association for Cancer Research (AACR) Annual Meeting 2023**

April 14–19, 2023; Orlando, Florida

**Chen MF**, Richards A, Evans P, et al. Comprehensive clinical and genomic analysis for patients with *MYC*, *MYCN*, and *MYCL* amplified solid tumors. Abstract 1394.

**2023 American Society for Therapeutic Radiology and Oncology (ASTO) Annual Meeting**

October 1–4, 2023; San Diego, California

**Cueto-Márquez AE**, Roy S, Tatebe K. Clinico-genomics model to predict survival in non-metastatic breast cancer: comparing the performance of machine learning models. Abstract 207.

## Honors and Awards

**Fawzi Abu Rous, MD**

2023 | Robert A. Chapman M.D. Outstanding Fellow Award

2023 | Fellow of The Year Award

2023 | Conquer Cancer American Society of Clinical Oncology (ASCO) Young Investigator Award

**Monica Chen, MD**

2023 | ASCO Conquer Cancer Young Investigator Award

**Jennifer A. Marks, MD**

2023-2024 | FDA-AACR Fellowship Program

**Joshua Reuss, MD**

2022 | Career Development Award by the LUNgevity Foundation

**Eric K. Singhi, MD**

2023 | Junior Faculty Travel Award, Hawaii Global Summit on Thoracic Malignancies

2023 | Co-director, Thoracic Medical Oncology Rotation for the MD Anderson Hematology/Medical Oncology Fellowship Program

2023 | Member, SWOG Cancer Research Network—Digital Engagement Committee

**Paul Stockhammer, MD, PhD**

2023 | Education award, International Association for the Study on Lung Cancer (IASLC)

# Start Planning for 2024!



## 6<sup>TH</sup> ANNUAL **EGFR RESISTERS RESEARCH SUMMIT**

Abstract submission deadline and forum details for EGFR-RRS 2024 coming soon. To be notified when the Call for Abstracts is distributed, please email [info@ceconcepts.com](mailto:info@ceconcepts.com).

Visit the Summit [website](#) for all things EGFR-RRS!

Follow us on  [@EGFRSummit](#)